MSB

1.02%

99.0¢ mesoblast limited

MESO Nasdaq update, page-1006

First 1006 Last

Share
Profile

Follow
bundeenabuoy

54 Posts.

3

15/08/20

10:27

Post #: 46561428
Share

Originally posted by mja: ↑

My impression was a lot of profit taking in context of a fearful event (35% decline earlier in the week) and a few sleepless nights. Many retail investors likely reduced holdings, as they are overestimating probability FDA does not approve for on label prescribing, and are worried they may wake up to a 25-35% decline if FDA does not approve.

Many traders may have had a 5% stop and woke up to a 20% gap down, so less speculators in the stock as this is not a stock they want to speculate in going forward after being burnt.

Most long-term holders were already heavily invested and so only a small amount of topping up. Many would be investors do not want to pay 50% more than the could have bought MSB for earlier in the week. Larger funds will have to get the analysts to review and provide a recommendation. Many analysts will overestimate the chance of FDA not approving. As if they state it is almost a 100% chance of approval given 9:1 with Advisory Committee, and it is not approved they are in the dog box and can forget about promotion.

These were the drivers on Friday. I would estimate the chance of FDA approval at 98-99%. So I would expect MSB to drift upwards, and should cross $5 early next week. Eventually, those not fully up to speed with MSB will see that FDA approval is a very, very high probability event and will see that acute GVHD underwrites MSBs present value and the accumulation will be begin in earnest. Once MSB gets FDA approval (assuming this happens), revenue models can be created, including probable remestemcel use in more markets eg Europe.

In my opinion Friday was a great day to accumulate, as MSB has been significantly de-risked. After a 9:1 recommendation, can anyone see the FDA not approving a treatment for innocent children who have no other option. This is not a treatment that anyone on the street would not want to be approved or people may have an underlying bias against. I'm sure people can think of expensive treatments for self inflicted/ acquired diseases that many in the public think should not be funded as their actions led to their predicament (not that I would agree as everyone makes mistakes). But, it is hard to argue that children who through no fault of themselves have a life threatening illness should not receive an available treatment.

Expand

I am long term holder but I have been sure before. I lost heavily on Getswift and Bigin.
You can argue logically the FDA will approve. My only worry is that the bigphamas will see MSB as life threatening to them. They will do everything legally and illegally they can do to stop approval. Should we be concerned or am I way off the mark?

MSB Price at posting: $4.70 Sentiment: Hold Disclosure: Held
11 Upvote

1 Great analysis

Reply

Top Stories

Microcap Wrap: 5 explorers with news out today

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

RCE

Recce's R327 found effective against E.coli during clinical trial

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

There are more pages in this discussion • 4,449 more messages in this thread...

First 1006 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 99.0¢		Change 0.010(1.02%)		Mkt cap ! $1.130B

Open	High	Low	Value	Volume
99.5¢	$1.02	98.5¢	$5.507M	5.501M

Buyers (Bids)

No.	Vol.	Price($)
1	9996	99.0¢

Sellers (Offers)

Price($)	Vol.	No.
99.5¢	18069	3

View Market Depth

No.	Vol.	Price($)
1	9996	0.990
2	32880	0.985
7	256748	0.980
3	27201	0.975
8	170032	0.970

Price($)	Vol.	No.
0.995	18069	3
1.000	26186	7
1.005	72373	3
1.010	82743	7
1.015	72242	5

Last trade - 16.10pm 28/06/2024 (20 minute delay)

MSB (ASX) Chart

MESO Nasdaq update, page-1006

Microcap Wrap: 5 explorers with news out today

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Ava Risk Group expands US presence with A$0.7M Substation Deal

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MESO Nasdaq update, page-1006

Top Stories

Microcap Wrap: 5 explorers with news out today

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Ava Risk Group expands US presence with A$0.7M Substation Deal

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News